Graves’ disease following administration of second dose of SARS-CoV-2 vaccine
Timothy James Goblirsch, Ambika E. Paulson, Gerti Tashko, Asefa Jejaw Mekonnen
Abstract
The SARS-CoV-2 vaccines have had an overwhelming success in curbing the COVID-19 global pandemic, accounting for countless lives saved. Adverse reactions are inevitable, given the vast scale of vaccination required to mitigate future surges of COVID-19. Hyperthyroid disorders have been reported as potential adverse reactions to SARS-CoV-2 vaccines in two patients with Graves' disease and a group of adults with subacute thyroiditis occurring in young women healthcare workers. We report a case of clinical Graves' disease in a woman with a previously stable multinodular goitre that occurred 14 days following her second dose of Pfizer-BioNTech SARS-CoV-2 vaccine.
Topics & Concepts
MedicineAdverse effectDiseaseGraves' diseaseVaccinationThyroiditisPandemicCoronavirus disease 2019 (COVID-19)PediatricsSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Intensive care medicineVirologyInternal medicineInfectious disease (medical specialty)Thyroid Disorders and TreatmentsErythrocyte Function and PathophysiologyAdrenal Hormones and Disorders